Successful treatment of T‐γ lymphoproliferative disease with human‐recombinant granulocyte colony stimulating factor | Zendy

Lang David F. | Zendy; Rosenfeld C. S. | Zendy; Diamond H. S. | Zendy; Shadduck R. K. | Zendy; Zeigler Z. R. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Successful treatment of T‐γ lymphoproliferative disease with human‐recombinant granulocyte colony stimulating factor

Author(s) -

Lang David F.,

Rosenfeld C. S.,

Diamond H. S.,

Shadduck R. K.,

Zeigler Z. R.

Publication year - 1992

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.2830400115

Subject(s) - granulopoiesis , granulocyte colony stimulating factor , immunology , cd8 , eosinophil , medicine , granulocyte , bone marrow , cd3 , cytotoxic t cell , t cell , t lymphocyte , biology , stem cell , chemotherapy , haematopoiesis , immune system , in vitro , biochemistry , genetics , asthma

A trial of recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) was attempted in a male with agranulocytosis, infection, and T‐gamma lymphoproliferative disease (T‐γ‐LPD). During five days of rhG‐CSF (960 μg/day), the absolute neutrophil count (ANC) increased from 0.0 to 4.5 K/μI. There were no changes in eosinophil or lymphocyte counts. In addition, there was no toxicity. Bone marrow cytotoxic/suppressor cells (CD57+/CD8+) were elevated (21.9%) before and decreased to 10.6% (normal < 12%) following rhG‐CSF. By contrast, there was no change in activated T cells (CD3+DR+) or T cell gene rearrangements. These findings suggest rhG‐CSF can improve granulopoiesis in T‐γ‐LPD, possibly by altering T‐cell mediated marrow suppression. © 1992 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research